SinoMab Bioscience is a bio-pharmaceutical company that focuses on research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases. SinoMab Bioscience offers monoclonal antibody-based biologics and new chemical entities for various indications against immunological diseases, with a flagship product SM03 (Suciraslimab) for the treatment of arthritis. The company generates substantial revenue from its commercialization process.
Headquarters
Units 303 And 305 To 307, No. 15 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok
Hong Kong; Hong Kong;
Contact Details: Purchase the SinoMab BioScience Limited (中国抗体制药有限公司) report to view the information.
Website: http://www.sinomab.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service